SerBut
Pharmaceutical compound
From Wikipedia, the free encyclopedia
SerBut, also known as O-butyryl-L-serine or as seryl-butyrate, is an ester conjugate of the short-chain fatty acid butyric acid (butyrate) and the amino acid serine.[1][2][3][4][5] It is a prodrug of butyric acid with high oral bioavailability and enhanced blood–brain barrier permeability in animals.[1][2][4][5] The drug makes use of amino acid transporters for absorption and transport.[3][4] It shows anti-inflammatory effects in rodents including in models of autoimmune diseases and neuroinflammation.[1][2][4][5] The use of butyric acid itself is hindered by its rapid metabolism in the gastrointestinal tract and other limitations.[4] The chemical synthesis of SerBut has been described.[4] SerBut was first described in the scientific literature by 2024.[1][2][4][5]
- None
| Clinical data | |
|---|---|
| Other names | O-Butyryl-L-serine; O-Butanoyl-L-serine; Serine–butyrate conjugate; Seryl-butyrate |
| Drug class | Butyric acid prodrug |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C7H13NO4 |
| Molar mass | 175.184 g·mol−1 |
| 3D model (JSmol) | |
| |
| |